Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Consensus Price Target of $87.38

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been given an average recommendation of “Moderate Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $87.38.

A number of analysts recently weighed in on KNSA shares. Canaccord Genuity Group upped their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. The Goldman Sachs Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Finally, Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th.

Kiniksa Pharmaceuticals International Price Performance

KNSA opened at $75.08 on Friday. The business has a fifty day moving average price of $76.04 and a 200 day moving average price of $60.75. Kiniksa Pharmaceuticals International has a 12 month low of $35.20 and a 12 month high of $82.94. The stock has a market capitalization of $5.86 billion, a price-to-earnings ratio of 77.40 and a beta of 0.09.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.30. The company had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. On average, research analysts anticipate that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 4,600 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the sale, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at $2,333,678.60. The trade was a 13.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the sale, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 51.98% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. Inspire Investing LLC purchased a new stake in Kiniksa Pharmaceuticals International during the first quarter worth approximately $1,698,000. BNP Paribas Financial Markets increased its stake in Kiniksa Pharmaceuticals International by 27.3% in the fourth quarter. BNP Paribas Financial Markets now owns 831,777 shares of the company’s stock valued at $34,311,000 after purchasing an additional 178,366 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Kiniksa Pharmaceuticals International in the first quarter valued at approximately $631,000. Headlands Technologies LLC acquired a new stake in Kiniksa Pharmaceuticals International during the second quarter worth approximately $1,161,000. Finally, SG Americas Securities LLC raised its holdings in Kiniksa Pharmaceuticals International by 18.2% during the first quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock worth $30,825,000 after purchasing an additional 98,783 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for patients with debilitating diseases, particularly conditions involving the immune system and inflammation. The company concentrates on areas of significant unmet medical need and uses biologic medicines and other targeted approaches in its research and development programs.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor.